This is a project to provide investment opportunities for pharmaceutical development in Iceland.
The target is a venture company that is a one of the representative venture company of Iceland.
In collaboration with the University of Iceland, they are conducting research and development on the drug activity of monocaprin and monolaurin as antibiotic lipids.
The founding member is a well-known researcher in the field of the Karolinska Institute, where the Nobel Prize in Physiology or Selection Committee is located. The system for applying for permits to the authorities for new formulations is in place.There is abundant financial needs for their development.